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Abstract
Background: Dexmedetomidine, a selective alpha-2 agonist, has sedative, analgesic, and anxiolytic effects without
respiratory depression. Dexmedetomidine can cause a biphasic cardiovascular response, and induce transient
hypertension. Hypotension is a common complication of spinal anesthesia. Decreasing anxiety of patients before
procedure is important for high quality of procedure. This study aimed to compare the incidence of hypotension
and patients’ anxiety and comfort levels when dexmedetomidine was intravenously administered before and after
spinal anesthesia.
Methods: Seventy-four patients with American Society of Anesthesiologists physical status classification I or II were
randomly allocated into two groups. Spinal anesthesia was performed using 12 mg of 0.5% heavy bupivacaine. In
Group A, 1 μg/kg of dexmedetomidine was intravenously administered for 10 min, followed by the maintenance
infusion of dexmedetomidine 0.2 μg/kg/hr after 5 min of intrathecal bupivacaine injection. Patients in Group B
received same dose of dexmedetomidine by intravenous administration before 5 min of intrathecal bupivacaine
injection. Perioperative vital signs, anxiety (using the Spielberger’s State-Trait Anxiety Inventory) and comfort
(using the numerical rating scale) were evaluated.
Results: The incidence of hypotension was significantly lower in Group A (16.1%) than in Group B (48.4%) during
infusion of dexmedetomidine (p = 0.01). The need for treatment of hypotension is higher in Group B than Group A
(p = 0.02). The incidence of bradycardia and desaturation did not significantly differ between the two groups. There
were no statistically significant differences regarding the patients’ anxiety and comfort.
Conclusions: Hypotension is more frequently occurred, and the treatment of hypotension is more needed in
Group B. The intravenously administration of dexmedetomidine before spinal anesthesia has no advantages in
hemodynamic status and patients’ comfort compared to that after spinal anesthesia during lower limb surgery.
Trial registration: ClinicalTrials.gov number, NCT02155010. Retrospectively registered on May 22, 2014.
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Background
Spinal anesthesia (SA) is commonly used for lower limb
surgery because it has a high success rate and can
maintain spontaneous ventilation. The hemodynamic in-
stability such as hypotension and bradycardia are the
most common side effects with SA [1, 2]. It may be
increased when sedatives is used with SA for decreasing
patients’ anxiety.
Patients want to be sedated during painful procedures
such as spinal tapping. Pre-sedation of patients can be
an important factor in the quality of SA. Propofol, mid-
azolam, and dexmedetomidine (DEX) have been
commonly used for sedation during SA. Propofol is a
profound respiratory depressant and midazolam has a
slight synergistic ventilatory depressive effect with SA
[3]. DEX, a selective α2-adrenoceptor agonist, causes
minimal or no respiratory depression, unlike other
sedatives [4].
Intravenous DEX as a rapid infusion caused biphasic
changes in heart rate (HR) and mean blood pressure
(MBP) [5]. Dyck et al. [5] found a 22% rise in the MBP
and a 27% decline in the HR within 4-5 min after start-
ing intravenous infusion of DEX. Although they infused
DEX at a high dose (2 μg/kg for 5 min), the administra-
tion of a bolus of 1 μg/kg DEX initially causes an
increase in BP for a brief period [6].
Also, DEX has anxiolytic effects and there is growing
interest in comparing efficacy, time to onset, and outcomes
between DEX and other anxiolytics such as midazolam [7].
DEX was as effective as higher dose (0.06 mg/kg) of mid-
azolam in preoperative sedation [8]. Anxiety-like behavior
is reduced by decreases in the circulating catecholamine
secretion after the administration of DEX [9].
Therefore, we evaluated the hemodynamic effects and
patients’ anxiety and comfort level according to the
timing of administration of DEX with SA.
Methods
Study design and patient population
This randomized, double-blind study enrolled seventy-
four patients from March, 2014 to July, 2015. This pro-
spective study was approved by the Institutional Review
Board of Inje University Haeundae Paik hospital
(129792-2014-003), and written informed consent was
obtained from patients (ClinicalTrials.gov number,
NCT02155010). This study protocol complied with the
1975 Declaration of Helsinki.
Criteria for inclusion and exclusion
Patients who were classified as American Society of
Anesthesiologists physical status I or II, aged 20-60
years, and scheduled to undergo lower limb surgery with
SA (expected surgical time <90 min) were included.
Patients with hypertension, diabetes mellitus (DM), or
heart disease (bradycardia or atrioventricular block) were
excluded.
Preoperative preparations and anesthesia protocol
No premedication was administered to the patients. While
in the operating room, all patients were monitored by
electrocardiography (ECG), pulse oximetry, non-invasive
blood pressure (NIBP), and bispectral index (BIS) values.
Before SA, crystalloid 6 mL/kg was intravenously injected
to the patients for hydration. A nurse who did not partici-
pate in this study prepared a 50 mL mixture of normal
saline 48 mL and DEX (Precedex®, Hospira Inc., Rocky
Mount, NC, USA) 200 μg. An anesthesiologist who did
not participate in this study performed SA. Patients were
randomly assigned to Group A and B (n = 37, each group)
(www.random.org). Patients were intravenously adminis-
tered 1 μg/kg of DEX for 10 min, followed by the
maintenance infusion of DEX 0.2 μg/kg/hr. Group A and
B were administered DEX after and before 5 min of spinal
anesthesia. Patients were placed in the lateral decubitus
position and a spinal tap in the L3/4 or L4/5 intervertebral
space was performed using the midline approach. After
confirming the free flow of the cerebrospinal fluid, 0.5%
heavy bupivacaine (Marcaine®, AstraZeneca AB,
Södertälje, Sweden) 12 mg was injected intrathecally. We
evaluated the disappearance of pinprick sensation by using
a needle in the mid-clavicular line. In addition, we
confirmed the extent of motor blockade by using the
modified Bromage scale [10]. The administration of DEX
was discontinued when the surgeon began to suture.
Following arrival in the PACU, patients stayed for one
hour. The patients were discharged from the PACU when
the modified Aldrete score was ≥ 9.
Measurements
MBP, HR, BIS values, and oxygen saturation were
recorded at baseline and at 5 min intervals during DEX
infusion and in the post-anesthetic care unit (PACU). The
primary outcome was comparison of the incidence of
hypotension between the two groups. Hypotension
(defined by a decrease in MBP below 20% of baseline),
bradycardia (HR < 50 beats per min [bpm]), and oxygen
desaturation (SpO2 < 95%) were recorded. Ephedrine
5 mg or atropine 0.5 mg was administered intravenously
when hypotension or bradycardia occurred. O2 3 L was
applied via nasal cannula when oxygen desaturation
occurred. The secondary outcome was comparison of
patients’ anxiety and comfort. The patients’ levels of anx-
iety experienced before (preoperative) and after (discharge
from PACU and postoperative 1st day) the study was
assessed using the Spielberger’s State-Trait Anxiety
Inventory (STAI) [11]. Patients’ comfort during (10 minutes
after SA) and after (discharge from PACU) this study was
assessed using the numerical rating scale (NRS, 0 = not as
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comfortable as imaginable, 10 = very comfortable). All data
were recorded by another anesthesiologist who did not
know when DEX was injected intravenously.
Statistical analysis
A sample size calculation was based on a pilot study
performed with 6 cases in each group. In the pilot study,
incidence of hypotension in Group A was 33% less than
in Group B. The requires number of patients for each
group was thirty-three (α =0.05, β =0.8). Assuming a
drop-out rate of 10%, the final sample size was set at
thirty-seven patients per group. The data are expressed
as mean ± standard deviation (SD), median (interquartile
range, IQR) or numbers of patients. Statistical analyses
were performed using repeated-measured analysis of
variance, the chi-squared test, the independent t test,
and the Mann-Whitney test. All statistical analyses were
performed using SPSS version 21.0 (SPSS Inc., Chicago,
IL, USA) and Medcalc 14.12.0 (MedCalc Software bvba,
Ostend, Belgium). A p-value < 0.05 was considered to
indicate statistical significance.
Results
A total of seventy-four patients were enrolled in this
study, but six patients per group were excluded from
data analysis. The final analyses included thirty-one
patients per group (Fig. 1).
Patients’ baseline characteristics were not different
between the two groups (Table 1).
The incidence of hypotension was significantly lower in
Group A (16.1%) than in Group B (48.4%) during infusion
of dexmedetomidine. The incidence of bradycardia and
desaturation did not significantly differ between the two
groups (Table 2). Also, the BIS values were not significantly
different between two groups during infusion of DEX
(Group A vs. Group B, 72.39 ± 8.96 vs. 71.16 ± 10.46).
The MBP and HR in the PACU were did not statistically
differ between the two groups. The mean HR (Group A
Fig 1 CONSORT flow diagram
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vs. Group B, 57.88 ± 6.16 vs. 59.49 ± 8.13, p = 0.133) and
MBP (Group A vs. Group B, 80.07 ± 12.48 vs. 77.49 ± 9.36,
p = 0.121) were not significantly different. Desaturation
did not occurred in the PACU in either group. The BIS
values of Group A and B were 88.94 ± 5.19 and 88.09 ± 5.96
in the PACU, respectively (p = 0.54).
The preoperative State Anxiety Inventory scale and
Trait Anxeity Inventory scale showed significant correl-
ation (r = 0.59, p < 0.0001). The State Anxiety Inventory
scale was decreased during the 3 assessment time
periods (p = 0.000), but this change was not significantly
different between the two groups (p = 0.66) (Table 3).
The median (IQR) comfort scores (NRS) of Group A
and B during infusion of DEX were 7 (5-9) and 8 (5-9),
respectively (p = 0.35). Also, the median (IQR) comfort
scores upon discharge from the PACU of Group A and
B were 7 (5-8.75) and 7 (5-8.75), respectively (p = 0.62).
There were no neurologic complications such as
paralysis or paresthesia.
Discussion
Infusion of DEX before SA can increase the incidence
rate of hypotension. Although perioperative anxiety was
decreased over time, there was no significant difference
in patients’ anxiety and comfort level according to the
timing of administration of DEX.
DEX has both analgesic and sedative properties that
may prolong the duration of SA [12, 13]. The intraven-
ous administration of DEX as premedication with SA
can be used widely without serious complications. Lee
et al. [14] and Park et al. [15] demonstrated that 0.5 or
1.0 μg/kg of DEX administered as an isolated bolus in
the absence of maintenance infusions prolonged the
duration of SA, and the incidence of hypotension was
found to be 15% and 0%, respectively. We injected an
intrathecal dose of 12 mg of heavy bupivacaine to the
patients. Although heavy bupivacaine 15 mg was intra-
thecally injected in another study [16], the incidence of
hypotension (0%-16%) was lower than that observed in
our study (16.1% and 48.4%). This might be attributed to
the single bolus administration of a low dose of DEX
(0.5 μg/kg).
A loading dose (1 μg/kg/10 min) of DEX was sufficient
for surgery of less than 60 min, and DEX infusion
followed by a maintenance dose (0.2 μg/kg/hr) was
sufficient for surgery within 90 min without delayed
recovery [17]. Thus, we used 1 μg/kg for 10 min for the
loading dose of DEX, followed by 0.2 μg/kg/hr for the
maintenance dose.
Early vasoconstrictive effects of DEX can induce
hypertension, but it could not offset the hypotensive ef-
fect of SA. Vasoconstrictive effects seem to be a transi-
ent phenomenon and cannot offset the vasodilation due
to SA. Rather, it seems that the hypotensive effect was
amplified by the SA and DEX in Group B. Also, stimula-
tion of the presynaptic α2-adrenoceptor by DEX causes a
dose-dependent decrease in the concentration of
norepinephrine in plasma and can reduce norepineph-
rine release by up to 92% in young healthy volunteers
[18]. So, we thought that hypotension was more
frequently occurred in Group B.
DEX premedication reduced the sympathoadrenal
response, analgesic requirements, and anxiety in intra-
venous regional anesthesia [19]. In addition, DEX may
have preventive effects against anxiety-like behaviors
and cognitive dysfunctions in rats with post-traumatic
stress disorder (PTSD) after repeated administration [9].
Hyperactivity of the noradrenergic systems is thought to
be a feature of PTSD and the attenuation of






Sex (male/female) 22/9 15/16 0.12
Age 35.87 ± 11.22 38.74 ± 12.27 0.34
ASA (1/2) 26/5 26/5 0.70
Height 170.25 ± 6.14 167.22 ± 9.34 0.14
Weight 71.22 ± 10.02 67.62 ± 12.10 0.21
Infusion time of DEX (min) 86.93 ± 17.78 86.61 ± 12.99 0.94
Injection site (L3-4/L4-5) 13/18 15/16 0.80
Maximum sensory block level T10 (8-10) T10 (8.5-10) 0.16
Values are expressed as number of patients, mean ± SD, and median (IQR). ASA
American society of anesthesiologists classification, DEX dexmedetomidine,
L lumbar, T thoracic dermatome, SD standard deviation, Injection site,
intrathecal heavy bupivacaine injection site, IQR interquartile range







Desaturation (Yes/No) 9/22 6/25 0.55
Bradycardia (Yes/No) 11/20 9/22 0.79
Hypotension (Yes/No) 5/26 15/16 0.01*
Frequency of injection of ephedrine
(0/1/2/3/4)
29/1/1/0/0 17/9/2/2/1 0.02*
Values are expressed as number of patients











Group A 45.52 ± 12.01 38.55 ± 8.04 34.55 ± 8.64 <0.001
Group B 43.65 ± 14.24 37.03 ± 10.51 34.90 ± 9.03 <0.001
Values are expressed as mean ± SD. SAI Spielberger’s State Anxiety Inventory
scale, PACU post-anesthetic care unit, SD standard deviation. The SAI was
decreased over time (p = 0.000), but this change was not significantly different
between the two groups (p = 0.66)
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noradrenergic activation by clonidine has been found to
ameliorate symptoms of PTSD [20]. Patients’ mean
anxiety scores (using the Anxiety Assessment Scale)
were significantly lower in the DEX group than in the
placebo group after MAC (monitored anesthesia care)
[21]. Therefore, we assumed that the decreasing of anx-
iety after surgery may be ascribed to the injection of
DEX in this study. We will need to evaluate State-Trait
Anxiety Inventory scale in a placebo group in further
studies. But, patients’ anxiety and comfort level was not
different regardless of the timing of sedation in our
study. It might be single shot spinal anesthesia is a
relatively easy and comfortable technique than epidural
anesthesia or peripheral nerve block to perform.
The routine administration of DEX is limited because
of the hypotension and bradycardia that may occur in
the postoperative period [6, 22]. The time for recovery
and discharge from the PACU was found to be longer
with DEX than in the placebo group [21]. We also
observed hypotension and bradycardia in the PACU.
These side effects were reversible with the administra-
tion of fluid therapy or drugs, but anesthetists should
beware of DEX infusion during the recovery time. The
benefit of DEX as sedative is that it can cause minimal
respiratory depression. However, we reported a relatively
high incidence rate (30%) of desaturation during infusion
of DEX. This may be because the definition of oxygen
desaturation (SpO2 < 95%) in our study was more
restricted than the definition applied in other studies
(SpO2 < 90%) [14, 15].
There are some limitations to this study. First, we did
not assess the differences regarding the duration of
sensory or motor blockade produced by SA with DEX
infusion. However, intravenous administration of DEX
before or after SA has been found to prolong the
duration of sensory and motor block in previous studies
[12, 16, 23, 24]. Second, we excluded geriatric patients
(>60 years) and those with hypertension and DM. There-
fore, further studies are needed to investigate the efficacy
of DEX in these patients.
Conclusions
The intravenous administration of DEX before SA was in-
duced more hypotension than the administration of DEX
after SA. The level of anxiety and comfort of the patients
was not different according to the timing of administra-
tion of DEX. The timing of infusion of DEX as sedative
with SA is more preferable after performing of SA.
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